Project Grant R01CA276430
Award Date
4/4/25
Completion Date
3/31/30
Dollars Obligated
$638K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) totaling $224,099 will support research at the University of California, San Diego (UCSD) to develop a targeted colorectal cancer (CRC) screening strategy for adults aged 45-49. The key objectives are to: Characterize the acceptability of CRC screening in this age group through a pilot trial and surveys/interviews to identify effective implementation strategies. Conduct a...
The National Cancer Institute (NCI) awarded a $696,852 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Harvard T.H. Chan School of Public Health. The grant will fund a 5-year research project to optimize a mobile messaging intervention for promoting colorectal cancer (CRC) screening among patients at community health centers (CHCs). The project aims to increase CRC screening rates, which are below national averages at CHCs, by leveraging text message...
This $1,793,830 federal Project Grant award was granted by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The primary recipient, the University of Kansas Medical Center Research Institute, Inc. (KUMCRI), will conduct a cluster-randomized trial across 20 primary care clinics serving communities with at least 25% Spanish-speaking patient populations. The study aims to compare the impact of a Normalization Process Theory-guided...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach involving DNA repair inhibition...
The National Cancer Institute (NCI) of the National Institutes of Health (NIH) awarded a $622,913 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of California, Los Angeles (UCLA). The grant, awarded on September 5, 2024, will fund a 5-year study to evaluate a multilevel intervention to increase colonoscopic follow-up rates after abnormal stool-based colorectal cancer screening tests among patients at federally qualified health centers...
This is a Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), totaling $1,239,420.00 and commencing on September 4, 2024. The award will fund a longitudinal observational study to assess changes in interoception (the brain's processing of internal bodily sensations) along the cancer chemotherapy continuum and its relationship to chemotherapy-induced peripheral neuropathy (CIPN) in 120 patients with breast...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $2,136,715.00 to Harvard College President & Fellows Of, specifically its Harvard T.H. Chan School of Public Health division. The award, effective August 1, 2024, aims to harness DNA methylation in peripheral blood for improved colorectal cancer prevention. The project will involve collaborations with Dana-Farber Cancer Institute and Boston...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides $627,422.00 to researchers at the Regents of the University of Michigan to develop a novel intervention against colorectal cancer associated with colibactin-producing bacteria. The project aims to optimize the surface display of an anti-toxin enzyme on commensal E. coli strains to neutralize the carcinogenic colibactin compound, thereby preventing DNA damage and reducing...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $547,047 to Georgetown University to test an innovative intervention to improve cancer screening and genetic testing rates among non-Hispanic Black and Hispanic women. The project will bundle multicancer screening (breast and colorectal) with navigation services and genetic risk assessment to address patient- and organization-level barriers that limit access to...
This $334,233 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program aims to conduct innovative research on cancer health disparities in South Carolina. The key products and services to be delivered include: Examining patterns of novel targeted cancer therapies and their impact on survival disparities by race, socioeconomic status, and urban/rural location. Describing the individual and joint effects of cancer treatment...